The FDA has issued an alert regarding a safety concern with certain Boston Scientific defibrillator leads used in implantable cardioverter defibrillators.
The affected models include Endotak Reliance, Reliance 4-site and Reliance 4-front defibrillation leads that use an expanded polytetrafluoroethylene-coated coil, according to an Aug. 6 news release from the agency.
The calcification of the defibrillation lead coils in the models may impair the device’s ability to deliver life-saving shocks during cardiac events. The affected leads may remain in the body for eight or more years before showing signs of failure, the release said.
Boston Scientific has reported 386 serious injuries and 16 patient deaths.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.